小米集團(01810.HK)發行6億美元債 獲超購7.5倍
小米集團(01810.HK)公布,全資附屬公司Xiaomi Best Time
International Limited於昨日發行2030年到期的6億美元優先票據,票面息率3.375%,於扣除包銷佣金等開支後,所得款項淨額將約為5.899億美元,將用於一般公司用途及償還現有借款。
小米表示,公開發行的境外債券即受到投資者追捧最終認購額達51億美元,較發行規模6億美元超額認購7.5倍。公司表示,受益於強勁需求,債券最終定價較初始價格指引收窄50個基點,為去年12月份以來亞洲投資級企業美元債券最大收窄幅度,票面息率料為中國TMT公司10年期債券史上最,冀降低公司長期融資利率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.